Contra: “Antidotes for novel anticoagulants?” – Do we really need them

Elise S. Eerenberg; Marcel Levi; Harry R. Buller

doi:10.1160/TH12-05-0298

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2012; 108(04): 623-624
DOI: 10.1160/TH12-05-0298

Pro/Contra Article

Schattauer GmbH

Contra: “Antidotes for novel anticoagulants?” – Do we really need them

Elise S. Eerenberg

^*Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

,

Marcel Levi

^*Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

,

Harry R. Buller

^*Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

› Author Affiliations

Abstract

Full Text

References

References
1 Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010; 103: 62-70.
2 Buller HR, Gallus AS, Pillion G. et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379: 123-129.
3 Levi MM, Eerenberg E, Lowenberg E. et al. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68-76.
4 Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?. Thromb Haemost 2011; 105: 574-578.
5 Haverkamp D, Hutten BA, Buller HR. et al. The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism. J Thromb Haemost 2003; 01: 69-73.
6 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
7 Crowther MA, Warkentin TE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 2009; 07: 107-110.
8 Fukuda T, Honda Y, Kamisato C. et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2011; 107: 253-259.
9 Zhou W, Schwarting S, Illanes S. et al. Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran. Stroke 2011; 42: 3594-3599.
10 Levi M, Levy JH, Andersen HF. et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-1800.
11 Martin A, Le-Bonniec B, Lecompte T. et al. Evaluation of recombinant activated facror VII, prothrombin complex concentrate and fibrinogen concentrate to reverse apixaban in a rabbit model (presented at the ACC 2012 meeting as an oral presentation). JACC (Supplement). 2012 59. Abstract 573.
12 Bijsterveld NR, Moons AH, Boekholdt SM. et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.